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Abstract
Background: At least 40% of people with psychosis have persistent distressing symptoms despite optimal
medication treatment. Cognitive behaviour therapy for psychosis (CBTp) is the only NICE-recommended individual
therapy for psychosis, with effects on symptoms, distress and quality of life. Yet <10% of service-users receive it and
94% of trusts struggle to provide it. Of those offered it, 22–43% refuse or do not attend. We have developed a new
pre-CBTp informed choice intervention to address knowledge and attitudes that influence uptake and
implementation and now want to test it in a feasibility trial.
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Methods: The design is a two-arm, feasibility randomised controlled trial (RCT), with 1:1 randomisation, stratified by
participant group and site. Participants are 40 psychosis patients and 40 clinicians, who are ambivalent towards uptake or
implementation of CBTp. Sites are community and inpatient services in Sussex and London. The intervention is a pre-CBT
digital psychoeducation intervention designed to address identified knowledge and attitudinal barriers to uptake and
implementation of CBTp, incorporating behaviour change mechanisms, and supported by animated introductory, patient
and clinician stories. The comparator is the NHS choices website for CBT. The primary aim is to assess clinical feasibility
(recruitment, randomisation, acceptability, use, delivery, outcome measurement, retention). A secondary aim is
a preliminary evaluation of efficacy. Outcomes will be assessed at baseline, post intervention, and one-month
follow-up (blind to treatment arm). The primary efficacy outcome is likelihood of offering/taking up CBTp. Secondary
outcomes include knowledge and attitudes towards CBTp, illness perceptions, empowerment, psychological wellbeing
(patients only) and CBTp implementation (clinicians only). Use of the intervention and CBT behaviours during the
follow-up period will be recorded and captured in a feedback questionnaire. Use, acceptability and experience of
outcome assessment will be explored in qualitative interviews with participants (n = 6 per group). The efficacy
evaluation will report descriptive data, key model parameters and 95% highest probability density intervals in a
Bayesian growth model.
Discussion: This is the first feasibility trial of a digital ‘informed choice’ decision aid for the implementation of CBTp. If
the trial proves feasible and demonstrates preliminary evidence of efficacy, a large multi-site trial will be warranted.
Trial registration: ISRCTN registry, ISRCTN53107879. Registered prospectively on 2 August 2017.
Keywords: Pre-CBT, Psychosis, Psychoeducation, Informed choice, Decision aid, Intervention, Feasibility, Pilot,
Implementation
Background
People who experience psychosis comprise approximately 1%
of the UK population (approximately 600,000 people). At
least 40% have persistent distressing symptoms, and poor re-
covery, despite optimal medication treatment. Apart from
the significant distress to patients, they make use of consider-
able NHS inpatient and community resources. The cost has
been estimated at £6.7 billion [1]. Cognitive behavioural ther-
apy for psychosis (CBTp) is the only NICE-recommended in-
dividual therapy for psychosis that is cost-effective [2–4] with
effects in reducing hospitalisation, symptoms and distress,
improving quality of life and social functioning [5–9]. Yet <
10% of service-users receive it and 94% of trusts struggle to
provide it [10, 11] with similar problems and levels of imple-
mentation occurring internationally [12]. Moreover, of those
offered it, 22–43% refuse or do not attend [13]. There is a
dearth of research into barriers to implementation in CBTp
[14] and research on uptake is also limited.
In terms of CBTp delivery, diffusion, dissemination
and implementation are progressively more active steps
in translating the evidence into practice [15]. Disse-
mination is the process of distributing information to
stakeholders, for example via guidelines, manuals and
training, but it is insufficient to produce sustainable
changes in practitioner behaviour [16]. Implementation
of evidence-based health care presents a serious
challenge and training transfer into routine practice is
notoriously problematic [17]. A number of strategies are
indicated to enhance implementation but no simple
solution has been identified [18, 19].
These implementation strategies incorporate six key
processes of planning, educating, financing, restructuring,
quality control and policy content [19]. In relation to
CBTp, identified barriers to implementation are consistent
with these processes and include issues with workforce
planning, shortages of trained staff and supervisors, limits
in funding and in organisational support. However, at an
individual level, limited knowledge and perceived
relevance of psychological therapies, such as CBTp, and
pessimistic attitudes on the part of clinicians also play a
part [20, 21]. Specifically, implementation requires some
change in the ‘adopter’ needs, motivations, values, goals
and skills towards CBTp, again emphasising clinician
knowledge, beliefs and attitudes. These cognitive factors
might include perceived relative advantage of CBTp com-
pared with other approaches, compatibility with one’s own
views, health and illness perceptions, complexity and ease
of use of the intervention and observability, or seeing it as
achievable, watching it in action and knowing that it
works [18, 22, 23]. Indeed, the Theory of Planned Behav-
iour requires that implementation is desirable, associated
with positive attitudes and perceived to be within beha-
vioural control [24], while Normalisation Process Theory
proposes that implementation requires coherence with
clinical practice, cognitive participation and engagement
with the processes of intervention delivery, collective ac-
tion of individuals, teams and services to support delivery,
and reflexive monitoring of the impact of intervention
delivery processes [25]. The knowledge and attitudes of
clinicians are thus argued to be key to implementation of
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psychological interventions in psychosis [26–28] with
some arguing that these attitudinal barriers may be at least
as important to address as therapeutic skill training [29].
Significant steps have been made in addressing barriers at
the organisational, financial, training and competency level
with the advent of Improving Access to Psychological
Therapies in Severe Mental Illness (Psychosis) (IAPT-SMI)
national pilot sites and agreed competencies for therapy de-
livery. Indeed, Jolley and colleagues reported a threefold in-
crease in accepted referrals for NICE-recommended CBTp
in a single year, when supported by strong organisational
readiness, established referral pathways, referral monitoring
and managerial support, ring-fenced funding for trained
therapists, and embedding within specialist psychosis ser-
vice where staff were knowledgeable about the difficulties
faced in psychosis and about appropriate treatments and
engagement approaches [30]. Newer brief, intensive
interventions may also help to improve implementation, as
they can be targeted and delivered in shorter time frames
[31–33]. However, there is still much to be done to increase
implementation. The London IAPT-SMI pilot delivered to
only 300 patients, from an estimated pool of 3500 eligible
participants, and brief intensive interventions are not yet
embedded within routine practice.
Only two small-scale qualitative studies in the UK
have investigated implementation at the individual clin-
ician level in terms of knowledge and beliefs, finding
that barriers exist in terms of beliefs about who is appro-
priate for CBTp, who will accept it, who will benefit and
who should deliver it [20, 21]. This pattern is repeated
internationally, with low priority given to CBTp by clini-
cians in a recent German study, influenced by lack of
availability of general and specialist CBTp training and
limited normalising illness beliefs [34]. Kimhy et al. also
found considerable knowledge gaps concerning the
evidence base for CBTp in the US, even in psychiatry
and psychology training directors [35].
However, improved implementation is only half of the
picture. Uptake of interventions in general [36–39], and of
CBTp in particular, may be hampered by health, illness
and treatment perceptions [40–42]. Illness perceptions in
psychosis patients also impact on quality of life [36–38].
Specific interventions, based on changing illness percep-
tions, have been effective in promoting adherence to and
outcomes from physical health interventions and have
emphasised the need to tailor these interventions to health
beliefs [43, 44]. Brief interventions that encourage more
adaptive beliefs about illness and informed choice regard-
ing psychological treatment in psychosis are clearly
needed [13, 45, 46], both to encourage uptake and to im-
prove outcomes.
Hence, problems exist both in implementation by clini-
cians and uptake by service-users, with significant potential
impact on prolonging distress and disability. NICE have
emphasised the need for research to consider knowledge
and beliefs when developing and evaluating interventions
aimed at behaviour change among individuals or popula-
tions [2]. Interventions drawing on implementation science
and health perceptions may provide the mechanism, while
information technologies may offer the means of delivery,
being easy to implement in routine care. Interactive
web-based interventions hold the potential to bridge the
‘quality chasm’ enabling the delivery of effective standar-
dised interactive materials, in accessible, flexible, cost and
time-efficient formats, blending a range of approaches, that
can be flexible to the knowledge, beliefs and behaviours of
individuals, incorporating motivational and behaviour
change techniques, and being readily refined through use
and feedback [47–53].
In summary, CBTp is an effective intervention for
distressing symptoms of psychosis yet few service-users
receive it. Despite the potential for increased capacity to
deliver CBTp through training, this has not translated
well into increased implementation or uptake. This is in
part hampered by gaps in knowledge and pessimistic
attitudes. There has been little research aimed at
addressing these gaps.
Research question
Is a randomised controlled trial (RCT) of a pre-CBTp
digital ‘informed choice’ intervention to improve know-
ledge, beliefs and behaviours of clinicians and service-users
feasible to be implemented?
Aims and objectives
This is the first feasibility RCT to develop and test a
pre-CBT digital ‘informed choice’ psychoeducation inter-
vention, designed to address identified knowledge and
attitudinal barriers to uptake by psychosis patients and
offers by clinicians of CBTp, and ultimately to improve
implementation. The primary research aim is to explore
trial methods, clinician and patient acceptability of the
interventions and outcome measures, and to provide
data to estimate the parameters required to design a
future RCT. The primary objectives are as follows:
1. To determine the number of participants who
accept referral and randomisation (benchmark set
at 80% of target for progression);
2. To evaluate the appropriateness of eligibility criteria
(ambivalence towards CBTp) by determining
feasible eligibility and recruitment rates at each site;
3. To assess retention through post-intervention and
one-month follow-up rates (benchmark set at mini-
mum 80% retention in line with previous studies);
4. To assess acceptability of the intervention, and
factors influencing this, through usage data in the
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follow-up period, feedback questionnaire responses,
and qualitative interviews;
5. To assess the acceptability and feasibility of the
outcome measures as methods to measure efficacy
of the intervention within a future trial.
Secondary objectives will be:
1. To measure and describe key outcomes post
intervention and at one-month-follow up (e.g. com-
pletion rates, likelihood of offering/referring or tak-
ing CBT). Descriptive statistics will be used to
quantify dropout and differences in mean responses
on key outcome measures over time within each
arm. Contingent upon the similarity of protocol for
a future trial to this feasibility trial, Bayesian models
may be fit to determine plausible estimates for the
effect of the trial under both informative and
uninformative priors.
We will not report significance tests as the feasibility
RCT was not designed or powered to test hypotheses or
to detect change. We have selected the NHS choices in-
formation about CBT as the comparison intervention as
this is the next best alternative online resource about




The design is a two-arm, multicentre, longitudinal, feasi-
bility RCT, with 1:1 block randomisation and varying
block size, stratified by participant group (clinician or
patient) and site (London or Sussex). Participants will be
randomised by Kings College London Clinical Trials
Unit, independently from the trial team, using an online
randomisation system. Randomisation will be initiated
by the research assistant immediately after the baseline
assessment and before intervention delivery. Allocation
will be confirmed by email. Baseline and one-month
follow-up data will be collected blind to allocation to en-
sure unbiased data collection. Post-intervention data will
not be collected blind to allocation as these data are col-
lected in a single session, immediately after intervention
delivery. Participants will not be blind and will be
reminded of the blind procedure at the start of the
one-month follow-up, in order to reduce the risk that
they reveal their allocation, and blind breaks will be re-
corded. For reporting the feasibility of the RCT, the
CONSORT (Consolidated Standards of Reporting Trials;
http://www.consort-statement.org/) extension to rando-
mised pilot and feasibility trials statement will be
followed [54]. For the protocol, the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) Figure and Checklist are provided in this paper
see: Fig. 1 and Additional file 1.
Setting
The setting will be secondary NHS community and in-
patient services in two geographically distinct NHS
Trusts: Sussex Partnership NHS Foundation Trust (rural
and urban) and South London and Maudsley NHS
Foundation Trust (urban inner city).
Participants
Participants will be 40 current psychosis patients and 40
clinicians working with people with psychosis, aged 16–65
years, who have expressed ambivalence towards uptake or
implementation of CBTp.
Inclusion criteria are:
 A current psychotic disorder diagnosis (F20-F29
ICD-10 diagnoses) as evidenced by clinical notes
and/or discussion with lead mental health profes-
sional (patients only);
 Receiving treatment from secondary mental health
services for psychosis or working as a clinician in a
secondary mental health service that delivers
treatments for psychosis;
 Age 16–65 years;
 Holding ambivalent views regarding CBTp, (defined as
a score of ≤ 7 on a 10-point Likert scale for likelihood
of taking up CBTp (patients) or offering/referring for
CBTp (clinicians).
Exclusion criteria:
 Lack of capacity to give informed consent;
 Insufficient grasp of the English language to enable
questionnaire completion;
 Cognitive impairment or learning disability which
precludes engagement with the study materials.
Trial flowchart
Figure 2 illustrates the trial flowchart.
Intervention development
The intervention was developed over three phases of
user-centred design and research process. The purpose
of these phases was: (1) to identify a rich set of issues af-
fecting uptake and implementation through a qualitative
study; (2) to identify the largest and most significant of
these issues in two large quantitative questionnaire
studies; and (3) to develop a broad set of intervention
components and to select the most important of these
through workshops and a Delphi consultation.
First, qualitative interviews were conducted with 37 clini-
cians and 27 patients with psychosis in order to determine
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the nature of knowledge and attitudinal barriers to uptake
and implementation of CBTp. The interviews were tran-
scribed and analysed thematically; the content was used to
develop the two knowledge and attitudes towards CBTp
questionnaires (described below). In phase 2, these
questionnaires were given to 206 clinicians and 206 pa-
tients; the data were used to identify the most significant
factors influencing uptake and implementation. In phase 3,
a user-centred design approach, and workshops with pa-
tients, clinicians and the research team, led by an industrial
designer and Uscreates, a health design agency, developed
and tested the design concepts, components and functions.
The initial stories and content were informed by the rich
qualitative data, questionnaire data and workshops. A
Delphi consultation with clinicians, patients, CBT trainers
and experts in digital therapy (n = 12) reached consensus
on components of the final intervention.
Intervention
The pre-CBT digital ‘informed-choice’ psychoeducation
intervention is a website with information, animated
stories and interactive elements, designed to address
identified knowledge and attitudinal barriers to uptake
and implementation of CBTp in clinicians and patients.
It provides honest, balanced and hopeful information,
incorporating behaviour change mechanisms derived
from the theory of planned behaviour, and models of
health perceptions, and is supported by animated intro-
ductory, patient and clinician stories. An interactive
goals section aims to encourage motivation, while the
stories, allow patients and clinicians to compare them-
selves to others with similar experiences, and to see
CBTp in action, and hear how it works. The intervention
includes sections on what CBTp is; how and whether it
works; what it can help with and for whom; how it
Fig. 1 Figure for Standard Protocol Items (SPIRIT) for an interventional trial of a pre-CBT digital ‘informed choice’ psychoeducation intervention
for clinicians who work with psychosis and their psychosis service users (the U&I study): schedule of enrolment, interventions, and assessments
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compares to alternative treatments; what CBTp might
be like, and advice on preparing to start CBTp. It also
contains handouts and sections for family and friends,
and for the whole clinical team, which aim to promote a
cohesive and supportive social and clinical network for
the implementation of CBTp. The animated stories are
an especially important component. They incorporate
key messages derived from the earlier stages of interven-
tion development. They can be watched either as
complete stories or in sections that illustrate the three
main topics: What is CBTp? What will it be like? And Is
CBTp for me?
The order of accessing the materials is fixed and partici-
pants are encouraged to visit the different sections in
order, following a journey represented by a sailing boat,
through the intervention, with a route map and arrows
that indicate the direction of travel. Although the partici-
pant can select their own ‘goals’ within the intervention
and print these, no data are saved, thus avoiding patients’
concerns about personal data security. Although the
intervention is designed for both patients and clinicians,
patients felt strongly that they should have access to the
same information as clinicians, while clinicians felt that
the intervention should be geared towards the needs of
patients; as such, only a single intervention platform was
developed.
The intervention will be delivered during a manualised
introductory session of up to 1-h duration, by a trained
research assistant. Access to the intervention will be
available for the subsequent month by computer or iPad,
before follow-up. No specific instructions will be given
for how or when participants should access the interven-
tion, but overall usage data will be recorded. Images of
the intervention are shown in Fig. 3.
The manual comprises a three-page document, which
describes how to introduce the digital intervention to a
Fig. 2 Trial flowchart for the U&I study feasibility RCT protocol
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clinician or a service user. The introduction explains: (1)
how the intervention has been developed; (2) the prom-
inent features of the intervention that are of relevance
for each type of user (clinician or service user); and (3)
the way in which each type of user might use the inter-
vention in the subsequent month. Subsequent sections
of the manual describe which sections of the
intervention to visit, in which order, for how long, and
which features and functions should be demonstrated
and content emphasised in each section. Finally, the
manual directs the research assistant to provide the user
with an information sheet with the website address and





Fig. 3 The intervention website. a The home page. b A patient’s story. c An interactive page
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Each research assistant who delivers the intervention
will be provided with the manual and the intervention
and will be required to practice delivery with and ask
questions of a trained colleague to ensure confidence
and competence before first use.
Comparator
The active comparator intervention is the CBT section of
the NHS choices website. It controls for attention and
intention and represents best-case routine care in relation
to CBT decision-making. It contains written text in five
sections: How CBT works; Uses for CBT; What happens
during a session; Pros and Cons of CBT; and Finding a
therapist. It also includes a short, written user story. It will
be presented in an equivalent session of up to 1 h, with a
printed summary sheet provided as a handout, alongside
the link to the website for use in the subsequent month.
All routine care and interventions will be permitted
throughout the duration of the study.
Assessments of outcome
Please refer to Fig. 1 (SPIRIT figure) for details of assess-
ment at each visit. The sample sizes have been deter-
mined by pragmatic means to establish the feasibility of
study and intervention procedures.
Primary feasibility outcomes
The primary purpose is to assess the feasibility of the in-
terventions in terms of acceptability, usability and accessi-
bility, and to examine the feasibility of methods of a future
trial including measures, recruitment procedures and trial
processes. This will be done through monitoring using the
study CONSORT diagram, through system analytics on
use of the digital intervention during the one-month
period, through the user feedback questionnaire collected
at the end of one month, and through a qualitative inter-
view with a sub-sample of those receiving the intervention
(n = 6 per group) at the end of one month. The primary
feasibility outcomes are:
1. Feasibility of eligibility criteria, recruitment and
retention within the NHS (numbers referred,
recruited, consented, randomised and retained in
the trial) during the trial recruitment period of
August 2017 to May 2018;
2. Feasibility of use, accessibility and acceptability of
the intervention and the outcome measures in the
NHS, measured using feedback questionnaire
responses regarding use of the intervention; activity
data on use of the intervention during the follow-up
period (average number of pages visited per partici-
pant), qualitative interviews with six patients and
six clinicians (three each in Sussex and London) re-
garding their experience of using the intervention,
the selection of outcome measures and participation
in the trial; September 2017 to May 2018.
Efficacy evaluation outcomes
Participants will complete the following measures at (1)
baseline, (2) immediately after introduction to the inter-
vention, and (3) at one-month follow-up.
1. Likelihood of offering/referring or taking up CBT
will be measured using a single Likert scale (0–10)
for how likely the participant is, in general, to offer/
refer psychosis patients for CBT, if this were
available, or how likely the participant is to take up
CBTp if it were offered today, each rated from not
at all (0) to extremely likely (10);
2. Knowledge and attitudes towards CBTp will be
measured using mean factor score for two new
questionnaires developed during earlier phases of
the current study. The clinician questionnaire
comprises 27 items, which form three factors (pro
CBT content, supportive CBT culture, confidence
in the value of CBT to patients), all with high
internal consistency (α = 0.87, 0.82 and 0.71,
respectively) and predictive validity for likelihood of
referring/offering CBTp (robust estimate of
correlation = 0.45, 0.53 and 0.32, respectively). The
patient questionnaire comprises 35 items, which
form four factors (positive attitudes towards CBTp,
personal barriers, doubt regarding efficacy and
fear related to CBTp), each with good internal
consistency (α = 0.94, 0.83, 0.76 and 0.82,
respectively) and predictive validity (robust estimate
of correlation = 0.50, 0.46 and 0.54, respectively),
except fear which was not a good predictor of
uptake (robust estimate of correlation = 0.26). In each
questionnaire, items are scored on a 7-point Likert
scale from disagree strongly to agree strongly;
3. Illness perceptions will be measured using the mean
factor scores for the modified illness perceptions
questionnaire [55] which has good internal
consistency (α = 0.70) and forms three factors
(cure/control, timeline, causes). The cure/control
and timeline factors have good internal reliability
and test–retest reliability (cure/control α = 0.09/0.09
and timeline α = 0.7/0.06). Individual items are
scored on a 5-point Likert scale from strongly agree
to strongly disagree;
4. Attitudes and behaviours towards CBTp
implementation will be measured using mean
scores for five constructs of the NOMAD tool [56]
adapted for CBTp implementation (clinicians only).
The tool includes three items that assess
normalisation of CBTp on a 0–10 Likert scale from
‘still feels very new’ to ‘feels completely familiar’,
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and 20 items that assess the four core constructs of
coherence of CBTp with standard care, cognitive
participation, collective action and reflexive
monitoring, each rated on a 5-point Likert scale
from strongly agree to strongly disagree;
5. Psychological wellbeing will be measured using the
CHOICE short-form measure of psychological well-
being (patients only). This scale has been produced
by our research group and has good psychometric
properties including internal consistency (α = 0.83),
test–retest reliability (ICC = 0.73), convergent valid-
ity (r = 0.52 with quality of life; − 0.58 with mood)
and sensitivity to change (t = − 0.41) [57]. The short
form used in the current study has been widely
used including in the national IAPT-SMI pilot sites
in the UK [30], and includes 11 items, and one per-
sonal goal item, each rated on a 0–10 Likert scale
from ‘worst’ to ‘best’. The total mean score will be
used;
6. Empowerment will be measured using the mean
factor scores for the Rogers’ Empowerment scale
(patients only) [58] which has good internal consistency
(α= 0.82) and factor structure with five factors: self-
esteem (α= 0.82); perceived power (α= 0.59); optimism
and control over the future (α= 0.45); community
activism/autonomy (α = 0.59); and righteous anger
(α = 0.64), with good convergent (hope/recovery
r = 0.67, empowerment r = 0.45) and predictive
validity (psychosis symptoms r = − 0.39). The scale
includes 28 items measured on a 4-point Likert
scale from strongly agree to strongly disagree;
7. CBT-related activities in the preceding month will
be based on interview and case notes screen (at
one-month follow-up).
The interview regarding CBT-related activities is part
of a larger interview to explore attitudes to and use of
the intervention during the follow-up period. The whole
interview takes approximately 10 min.
Procedure
Clinician and patient participants will be identified
through research staff presentations at team meetings,
clinics, training events and following email and tele-
phone contact with staff.
Clinician participants will be approached by a research
assistant and patient participants by their lead clinician.
All interested potential participants will be provided
with the study information sheet and will have the op-
portunity to discuss the study in a meeting or telephone
conversation with a research assistant who is trained in
taking informed consent and in Good Clinical Practice.
Following informed consent, participants will complete the
basic demographic information and baseline questionnaire
measures. They will then be randomised to either the
intervention or comparison condition. The intervention or
comparison condition will be provided according to a man-
ualised protocol as part of a single session lasting up to 1 h,
after which participants will also complete the same ques-
tionnaires in the post-intervention assessment in the same
session.
Participants in the intervention condition will be
provided with access to the online intervention for the
subsequent month. Where a patient participant does not
have access to a computer, they will be provided with an
iPad, locked to the intervention site, to enable access in
the subsequent month. Usage data will be tracked
through Google Analytics and will be stored safely and
confidentially; data willonly be accessible to the re-
searchers via a password. Usage data will be stored in an
encoded format that prevents tampering. Comparison
participants will be provided with the NHS choices web-
site link and handout. This website is publicly available.
After one month (− 2/+ 8 weeks), each participant will
complete the same questionnaires in a follow-up assess-
ment, which will be conducted by a research assistant
who is blind to randomisation arm, in person or by
telephone. All participants in the intervention arm will
also complete a brief feedback questionnaire on their
use of the intervention.
A small subsample of six patients and six clinicians
who receive the informed choice intervention materials
will also undertake a brief semi-structured interview
with a research assistant to explore their experience of
using the intervention materials and to provide feedback
to further refine the intervention.
Analysis plan
Descriptive data will be used to report referrals, recruit-
ment, retention, use of the intervention and CBTp-related
behaviour. Audio-recorded qualitative interviews will be
transcribed and themes will be extracted using Inter-
pretative Thematic Analysis. Themes will be translated into
recommendations for refining the intervention, trial proce-
dures, outcome measures and protocol in preparation for a
future RCT, if feasibility and preliminary efficacy data are
promising. There will be a preliminary examination of the
data after 10 participants per group have been recruited. If,
at that stage, the intervention and protocol are regarded as
sound and needing no significant refinement, the study will
proceed to recruit the full 40 participants per group. If
there is need for further refinement, the study will allow for
successive refinement of the protocol with the next 10 par-
ticipants per group until the trial team are satisfied that the
final protocol is optimal. If the protocol changes during
data collection descriptive statistics will be reported (where
feasible) by timepoints at which protocol changes were
made. These will not be used to inform a subsequent trial,
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but only to describe what happened in the current trial. If
the protocol does not change during data collection and,
therefore, a subsequent trial would adhere to the current
protocol, descriptive statistics will be reported; a Bayesian
growth model will also be fit to the data, blind to study
arm, treating change over time as a random effect within
participants and randomisation arm as a time-invariant
fixed effect. 95% highest probability density (HPD) intervals
will be used to estimate plausible values of the key model
parameters (notably the parameter quantifying the diffe-
rence between the arms in the rate of change of the likeli-
hood of taking up/referring to CBT). Bayesian growth
model parameters are estimated using an iterative process
(Markov chain Monte Carlo [MCMC]) and missing values
are estimated as unknown parameters [59] in a process akin
to multiple imputation [60]. To check the influence of
priors of the model estimates, model fit with both infor-
mative and uninformative priors will be compared.
Data management and security
Data storage and confidentiality will be ensured, in line
with the Data Protection Act 1998 and the NHS Code of
Practice for Confidentiality. All personally identifiable
data will be kept separately from anonymised research
data and all data will be stored in secure
password-protected files, available only to the study
team, on Sussex Partnership NHS Foundation Trust pro-
tected access shared drives and in locked filing cabinets.
Study data will be identified using a participant identifica-
tion number (ID). This ID will be linked to the participant’s
name in a password protected link file. Audio-recording
equipment will be used to record qualitative interviews re-
garding the experiences of taking part in the intervention
and the trial. These audio files, named with the unique
participant identifier, will be stored as computer files on
secure NHS servers in an anonymised and encrypted form.
The digital intervention will record how patients and
clinicians use the intervention over the month that they
have access, including which pages are accessed and
how frequently. Only data about use of the package will
be stored. No personal data will be stored. Usage data
will be tracked through Google Analytics and stored
safely and confidentially in an encoded and password-
protected format that prevents tampering and that is
only accessible to the researchers.
Data quality
Data quality will be ensured by close monitoring and
routine auditing for accuracy. The main feasibility and
pilot outcome data will be checked for every participant
by comparing the paper record with that on the data-
base, once all possible assessments for each time point
have been completed. An error rate of no more than 5%
is acceptable. If an error rate > 5% is found, advice will
be sought from the trial statistician regarding further
data checking.
Study governance
Sussex Partnership NHS Foundation Trust is the spon-
sor for this study. The trial has received a favourable
ethical opinion from London-Dulwich research ethics
committee (reference 15/LO/0041; IRAS number
176709). The trial will be conducted in compliance with
the principles of the Declaration of Helsinki [61], the
Medical Research Council Guidelines for Good Clinical
Practice [62] and in accordance with all applicable regu-
latory requirements including the Research Governance
Framework and the Mental Capacity Act 2005 [63]. The
chief investigator will have overall responsibility for the
trial dataset, supported by the trial oversight group. The
sponsor and REC will be provided with direct access to
source data and other documents if required for REC re-
view and trial monitoring. The trial management group
will meet approximately fortnightly to review trial con-
duct and a trial oversight group and patient and public
involvement group will meet approximately every 3–6
months to oversee study conduct, analysis and out-
comes, including recruitment and data completion. The
trial oversight group will comprise members of the study
team who are not involved with the day to day running
of the study. They will approve the protocol and amend-
ments and in this feasibility study will undertake DMEC
duties. The trial is registered at ISRCTN (reference
14678860), a primary clinical trial registry recognised by
WHO and ICMJE. Individual participants will have the
right to withdraw from the trial at any time. Any serious
adverse events will be reported to the trial oversight
group. The trial may be prematurely discontinued by the
sponsor, chief investigator or on the basis of new safety
information or for other reasons by the oversight group,
regulatory authority or Ethics Committee. The trial may
also be prematurely discontinued due to lack of recruit-
ment. If the study is prematurely discontinued, active
participants will be informed and no further participant
data will be collected.
Public involvement
Patient and public involvement (PPI) has been central
throughout the entire project. A patient co-applicant with
lived experience of psychosis co-ordinated the PPI and
with PPI members with psychosis, co-led on developing
the research question, and collaborated and provided rich
perspectives on the design, ethics, recruitment, delivery
and dissemination strategy, part-funded by a Research
Design Service PPI grant. Key impacts included the focus
on patient uptake alongside implementation and the in-
corporation of feedback from those who have used the
intervention to inform future users. They emphasised the
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potential of the intervention to raise awareness and under-
standing of CBTp and thus improve uptake, provide goals,
offer hope for recovery and impact on important
wellbeing outcomes, which were incorporated into the
outcome measures. The PPI lead and a designated
service-user researcher contributed to earlier phase data
collection, qualitative analysis and questionnaire develop-
ment. A study-specific advisory group co-facilitated with
the PPI lead have advised on the intervention materials
and interpretation of earlier phase outcomes. They will
continue to meet approximately every three months to
provide input to the study and steering group regarding
recruitment, evaluation and dissemination of results.
Dissemination
Results will be presented from different perspectives
(patient, clinician, trainer) and to a range of audiences,
through patient and public, and academic peer-reviewed
journals. All study co-applicants and research assistants
will contribute to all study publications; all study
publications will be submitted for review to the National
Institute for Health Research before publication.
Discussion
This trial represents the initial feasibility RCT of the first
pre-CBT informed choice intervention. The intervention
has been designed following extensive qualitative and
quantitative analysis and user-centred design research. It
focusses on the needs, knowledge and attitudes of psych-
osis patients and clinicians, and is a psycho-educational
and decision-aid tool to facilitate high quality, informed
and collaborative discussions and choices regarding the
implementation and uptake of CBT for psychosis. The
study will explore feasibility, accessibility, acceptability
and utility of the intervention in routine clinical practice
in the NHS to inform the design for a future RCT. The
careful assessment of feasibility will help to ensure ef-
fective future implementation within the NHS of the
digital intervention [64].
We initially planned to develop two interventions: one
for patients and one for clinicians, each addressing their
unique needs, but during intervention development it be-
came apparent that clinicians felt that the intervention
should be focused on the needs of patients and patients felt
equally that they should have access to the same informa-
tion as clinicians. For these reasons, we developed a single
intervention, but it will be important to understand the ex-
tent to which this truly addresses the needs and barriers for
clinicians offering CBTp alongside those of patients.
The qualitative and quantitative feasibility feedback
will enable us to determine how and when in a patient’s
journey, or a clinician’s interaction with their patients,
the intervention would be most appropriate and most
valuable. It will also enable us to understand where and
in what format the intervention might be most accept-
able and accessible, bearing in mind both the strengths
and limitations of an online intervention.
The inclusion of two sites each with a different ethos
and organisational structure relating to CBTp will enable
us to more readily generalise our learning to a range of
NHS trusts and services.
Understanding and evaluating the ambivalence of cli-
nicians and patients towards a NICE-recommended
intervention requires sensitivity. An important outcome
of the feasibility and pilot work will be to determine the
best way to recruit to the study, capture ambivalence
and evaluate outcomes in a study of this type. It may
also provide some preliminary indication of the likely
size of changes in knowledge, attitudes, intentions and
behaviours towards CBTp.
The inclusion of measures of health perceptions and
attitudes towards implementation will allow us to under-
stand the factors that influence attitudes at baseline and
will provide indicators of potential change mechanisms.
Further indications of change mechanisms will be ob-
tained from the qualitative feedback regarding which
psychoeducation and behavioural change components
were most used and most valued.
The final outcome from this study will be a robust
protocol for a future RCT to test the effectiveness of the
first digital ‘informed choice’ intervention to promote up-
take and implementation of CBT for psychosis, as well as
to explore purported mechanisms of action. The interven-
tion has the potential to provide a valuable benchmark to
enable high quality, collaborative discussions and offers of
CBTp by clinicians, as well as empowering patients to
make informed choices about uptake. If effective, this
intervention or ‘therapeutic decision aid’ may pave the
way for the development of additional decision aids to
support informed choices about other psychological and
non-pharmacological approaches, thus enabling these in-
terventions to be better matched and targeted to patient
needs and preferences.
Trial status
Recruitment of participants commenced in August 2017
and will be open until May 2018. The date of first enrol-
ment is August 2017.
Additional file
Additional file 1: SPIRIT Checklist for the U&I Project. (DOC 121 kb)
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